ALZN 株価分析 — Alzamend Neuro Inc (Healthcare >> Biotechnology)
ALZN に関するよくある質問
ALZNのROE(自己資本利益率)は?
Alzamend Neuro IncのROEは-1,196.43%です。
ALZNの配当利回りは?
Alzamend Neuro Incの配当利回りは0.00%です。
ALZNの品質スコア(Quality Score)は?
当社のAIはALZNの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ALZNは今が買い時ですか?
当社AIのタイミングスコアは100点中6点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ALZNはどのセクターに属しますか?
Alzamend Neuro IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
ALZN AI Analysis Summary
Our AI summary for ALZN: Alzamend Neuro Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -1,196.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 6/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.38
Price
-0.05
(-3.50%)
Day Change
|
|
|---|
ALZN, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.38 |
| PBV / Sector |
6.28 / 5.21
|
| Earning Per Share | -2.63 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-07 08:11:17 |
| Symbol | ALZN |
| Name | ALZAMEND NEURO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.79 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.61 / 9,672.56 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3480 Peachtree Road NE, Atlanta, GA, United States, 30326
Phone: 844 722 6333
Website: https://www.alzamend.com
Sector: Healthcare >> Biotechnology
Description: Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google